Wenwen Cui

Wenwen Cui

Auto-generated profile, based on publicly available information

Wenwen Cui

College of Integrated Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050035, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Pharmaceutical Biology
Verified
Journal Article
Open access
YHYuan-Yuan Hao
Yuan-Yuan Hao
WCWen-Wen Cui
Wen-Wen Cui
HGHuai-Lin Gao
Huai-Lin Gao
MWMing-Ye Wang
Ming-Ye Wang
YLYan Liu
Yan Liu
ZJZhenhua Jia
Zhenhua Jia
Jinlida (JLD) as a traditional Chinese medicine formula has been used to treat type 2 diabetes mellitus (T2DM) and studies have shown its anti-obesity effect.To investigate the therapeutic effects ...

26 July 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WCWenwen Cui
Wenwen Cui
SXShen Xin
Shen Xin
LZLingjuan Zhu
Lingjuan Zhu
MWMingye Wang
Mingye Wang
YHYuanyuan Hao
Yuanyuan Hao
YHYunlong Hou
Yunlong Hou
Objective. The aim of this study was to determine whether Si-Miao-Yong-An decoction (SMYAD) could protect cardiomyocytes from ischemia/reperfusion (I/R) injury and its underlying mechanisms. Methods. C57BL/6 mice were used to establish a model of myocardial infarction by I/R injury and treated by SMYAD for 4 weeks. Then, the cardiac functions of mice were evaluated by cardiac magnetic resonance (CMR). Histopathological analysis for the heart remodeling was detected by H&E and Masson staining. The protein expression of collagen I, MMP9, and TNFα was detected by western blot in the heart tissues. H9C2 cells were used to establish the hypoxia/reoxygenation (H/R) model and SMYAD intervention. MTT assays detected the cell viability of myocardial cells. The expression level of IL-1β was evaluated by ELISA. The expression levels of LC3B-II/LC3B-I, p-mTOR, mTOR, NLRP3, procaspase 1, and cleaved-caspase 1 in H9C2 cells were evaluated by Western blot. Results. SMYAD improved cardiac functions such as ventricular volume and ejection fraction of the rats with ischemia/reperfusion injury. Morphological assay indicated that SMYAD reduced the scar size and inhibited fibrosis formation. It was found that SMYAD could regulate collagen I, MMP9, and TNFα protein expression levels in the heart tissues. SMYAD improved the survival rate of H9C2 cardiomyocytes in the H/R injury model. SMYAD elevated the rate of LC3B-II/LC3B-I protein expression, decreased the rate of p-mTOR/mTOR protein expression, and reduced expressions of caspase 1, NLRP3, and IL-1β in H/R cardiomyocytes. Conclusion. SMYAD exerted protective effects on ischemia/reperfusion injury in myocardial cells by activating autophagy and inhibiting pyroptosis. This might be the reason why SMYAD protected myocardial tissue and improved cardiac function in mice with ischemia/reperfusion.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WCWenwen Cui
Wenwen Cui
YHYuanyuan Hao
Yuanyuan Hao
MWMingye Wang
Mingye Wang
QZQiuyan Zhang
Qiuyan Zhang
JWJunmei Wang
Junmei Wang
YHYunlong Hou
Yunlong Hou
Objective. L‐3‐n‐Butylphthalide (NBP) is used to treat moderate and severe acute ischemia stroke. A previous screening study indicates that XY03‐EA, a novel derivative of NBP, is more potent than NBP in the oxyradical scavenging capacity. In this study, in vivo and in vitro ischemia/reperfusion (I/R) models were used to test whether the XY03‐EA offered therapeutic benefits in the ischemic stroke and explore the underlying mechanism of action. Methods. For this purpose, behavioral scores, cerebral infarct volume, cerebral blood flow, oxidative stress levels, inflammatory factor expression, energy metabolism levels, and autophagy activation were estimated in the rat middle cerebral artery occlusion and reperfusion (MCAO/R) model. The nonhuman primate MCAO/R model was conducted to validate the therapeutic effect of XY03‐EA applied for 3 weeks. The neurological deficit score (NDS) progression rate and the infarct volume were continuously recorded on days 3, 7, 14, and 21. The PC‐12 cell OGD/R model was used to assess the cell survival rate, reactive oxygen species (ROS) levels, the expression of autophagy execution molecules, and the activation of autophagy‐related signaling pathways. Results. XY03‐EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03‐EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose‐dependent way. Mechanistically, XY03‐EA inhibited ROS‐dependent autophagy activation and thereby protected the PC‐12 cells from the autophagic cell death induced by OGD/R. Conclusions. In this study, we found that XY03‐EA alleviated the cerebral I/R injuries in rats and nonhuman primates. Our results demonstrated that XY03‐EA exerted neuroprotective effects against the ROS‐mediated autophagic neurocyte death and had great potential for the treatment of ischemic stroke.

10 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
WCWenwen Cui
Wenwen Cui
XSXin Shen
Xin Shen
LZLingjuan Zhu
Lingjuan Zhu
MWMingye Wang
Mingye Wang
YHYuanyuan Hao
Yuanyuan Hao
YHYunlong Hou
Yunlong Hou
Objective :The aim of this study was to determine whether Si-Miao-Yong-An decoction (SMYAD) could protect cardiomyocytes from ischemia/reperfusion (I/R) injury and its underlying mechanisms. Methods: C57BL/6 mice were used to establish a model of myocardial infarction by I/R injury and treated by SMYAD for 4 weeks. Then the cardiac functions of mice were evaluated by Cardiac Magnetic Resonance (CMR). Histopathological analysis for the heart remodeling was detected by H&E and Masson staining. The protein expression of Collagen I, MMP9 , and TNFα was detected by Western blot in the heart tissues. H9C2 cells were used to establish the hypoxia/reoxygenation (H/R) model and SMYAD intervention. MTT assays detected the cell viability of myocardial cells. The expression level of IL-1β was evaluated by ELISA. The expression levels of LC3B-II/LC3B‑I, p- mTOR, mTOR, NLRP3, pro-Caspase1, and cleaved-Caspase1 in H9C2 cells were evaluated by Western blot. Results : SMYAD improved cardiac functions such as ventricular volume and ejection fraction of the rats with ischemia/reperfusion injury. Morphological assay indicated that SMYAD reduced the scar size and inhibited fibrosis formation. It was found that SMYAD could regulate Collagen I, MMP9, and TNFα protein expression levels in the heart tissues. SMYAD improved the survival rate of cardiomyocytes H92C in the H/R injury model. SMYAD elevated the rate of LC3B-II/LC3B‑I protein expression, decreased the rate of p-mTOR/mTOR protein expression, and reduced expressions of Caspase 1, NLRP3, and IL-1β in H/R cardiomyocytes. Conclusion: SMYAD exerted protective effects on ischemia-reperfusion injury in myocardial cells by activating autophagy and inhibiting pyroptosis. This might be the reason why SMYAD protected myocardial tissue and improved cardiac function in mice with ischemia/reperfusion.